ClinicalTrials.gg
CompletedNCT05325203Updated Mar 18, 2024

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

A Phase 3 interventional study of Ongericimab and Placebo in Heterozygous Familial Hypercholesterolemia, sponsored by Shanghai Junshi Bioscience Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Shanghai Junshi Bioscience Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Hyperlipoproteinemia Type II with a site in China — 13 open to participants now, 13 under way, 7 of them phase 3. Hyperlipoproteinemia Type II · China.

Enrollment
12th of 22
135 · median 142
Started
2021
with 3 others
Phase 3
13 of 24
6 open now
Registered
9th of 24
by date

Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, this one is the 12th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2021, is one of 13 in phase 3, and was the 9th registered.

Hyperlipoproteinemia Type II

251 studies on the registry are indexed under Hyperlipoproteinemia Type II; 57 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

13 of the 24 studies in Hyperlipoproteinemia Type II with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Hyperlipoproteinemia Type II studies recruiting now, 17 (46%) set no upper age limit and 16 (43%) stop at 75 or younger; 17 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hyperlipoproteinemia Type II with a site in China, or all of them as a file.
02

Study summary

JS002 is a recombinant human anti-PCSK9 monoclonal antibody.The study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study in Chinese patients with heterozygous familial hypercholesterolemia (HeFH). Objective To evaluate the efficacy and safety of JS002 150 mg (Q2W) and 450 mg (Q4W) subcutaneous injection (SC).

Read the detailed description

A randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of JS002 in patients with heterozygous familial hypercholesterolemia. 120 subjects are planned to be enrolled. Each subject is required a maximum of 6 weeks of screening, 24 weeks of treatment, and 8 weeks of follow-up. To evaluate the lipid-lowering efficacy of subcutaneous injection of JS002 at 24 weeks compared with placebo in heterozygous familial hypercholesterolemia patients under optimized lipid lowing therapy . Subjects meeting the study inclusion criteria will be randomly assigned in a 2:1:2:1 ratio to JS002 150 mg Q2W or JS002 450 mg Q4W or matched placebo to receive the study drug (JS002) or placebo subcutaneously for 24 weeks.

treatment cohorts: JS002 150mg Cohort:JS002 150mg or placebo treatment(JS002 :Placebo=2:1) Q2W JS002 450mg Cohort:JS002 450mg or placebo treatment(JS002 :Placebo=2:1)Q4W

03

Conditions studied

  • Heterozygous Familial Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Males and females ≥ 18 to ≤ 80 years of age
  3. DLCN>8 in HeFH
  4. Stable lipid-lowering therapies for at least 4 weeks
  5. Patients with ASCVD LDL cholesterol≥1.4mmol/L at screening Patients without ASCVD LDL cholesterol≥2.6mmol/L at screening
  6. Triglyceride≤4.5 mmol/L(400 mg/dL);

Exclusion criteria

Exclusion Criteria:

  1. HoFH or meet the diagnostic criteria of HoFH
  2. (NYHA) class III or IV or last known \< 30%
  3. History of uncontrolled arrhythmia within 90 days
  4. Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 90 days of randomization
  5. Planned cardiac surgery or revascularization.
  6. Uncontrolled diabetes mellitius (>8.0%).
  7. Uncontrolled hypertension.
  8. Other conditions that the researchers considered inappropriate to participate in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    JS002 150mg Q2W for 24 weeks

    40 patients will be enrolled in this arm

    Biological: Ongericimab

  • Placebo comparator
    placebo 150mg Q2W for 24 weeks

    20 patients will be enrolled in this arm

    Drug: Placebo

  • Experimental
    JS002 450mg Q4W for 24 weeks

    40 patients will be enrolled in this arm

    Biological: Ongericimab

  • Placebo comparator
    placebo 450mg Q4W for 24 weeks

    20 patients will be enrolled in this arm

    Drug: Placebo

Interventions

  • BiologicalOngericimab

    Administered by subcutaneous injection

    Also known as: JS002

  • DrugPlacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24

    LDL-C was quantified using the enzymatic colorimetric assay

    Time frame: Baseline and week 24

Secondary outcomes

  1. Absolute Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24

    LDL-C was quantified using the enzymatic colorimetric assay

    Time frame: Baseline and Week 24

  2. Percentage changes From Baseline in the Total Cholesterol at week 24

    TC was quantified using the enzymatic colorimetric assay

    Time frame: Baseline and Week 24

  3. Absolute changes From Baseline in the Total Cholesterol at week 24

    TC was quantified using the enzymatic colorimetric assay

    Time frame: Baseline and Week 24

  4. Percentage changes From Baseline in Non-HDL-C at Week 24

    Non-HDL-C was quantified using the Calculation,TC minus HDL-C

    Time frame: Baseline and Week 24

  5. Absolute changes From Baseline in Non-HDL-C at Week 24

    Non-HDL-C was quantified using the Calculation,TC minus HDL-C

    Time frame: Baseline and Week 24

  6. Percentage changes From Baseline in Apo B at Week 24

    Apo B was quantified using the turbidimetric immunoassay(TIA)

    Time frame: Baseline and Week 24

  7. Absolute changes From Baseline in Apo B at Week 24

    Apo B was quantified using the turbidimetric immunoassay(TIA)

    Time frame: Baseline and Week 24

  8. Percentage changes From Baseline in Lp(a) at Week 24

    Lp(a) was quantified using the turbidimetric immunoassay(TIA)

    Time frame: Baseline and Week 24

  9. Absolute changes From Baseline in Lp(a) at Week 24

    Lp(a) was quantified using the turbidimetric immunoassay(TIA)

    Time frame: Baseline and Week 24

  10. Percentage changes From Baseline in HDL-C at Week 24

    HDL-C was quantified using the enzymatic colorimetric assay

    Time frame: Baseline and Week 24

  11. Absolute changes From Baseline in HDL-C at Week 24

    HDL-C was quantified using the enzymatic colorimetric assay

    Time frame: Baseline and Week 24

  12. Percentage changes From Baseline in Apo A1 at Week 24

    Apo A1 was quantified using the turbidimetric immunoassay(TIA)

    Time frame: Baseline and Week 24

  13. Absolute changes From Baseline in Apo A1 at Week 24

    Apo A1 was quantified using the turbidimetric immunoassay(TIA)

    Time frame: Baseline and Week 24

  14. Percentage changes From Baseline in TG at Week 24

    TG was quantified using the enzymatic colorimetric assay

    Time frame: Baseline and Week 24

  15. Absolute changes From Baseline in TG at Week 24

    TG was quantified using the enzymatic colorimetric assay

    Time frame: Baseline and Week 24

  16. The ratio of TC/HDL - C

    Calculation

    Time frame: Baseline and Week 24

  17. The ratio of Apo B/Apo A1

    Calculation

    Time frame: Baseline and Week 24

  18. Percentage of Participants With 50% or Greater Reduction in LDL-C From Baseline at Week 24

    Calculation

    Time frame: Baseline and Week 24

Other outcomes

  1. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    ADA was quantified using the Bridging-ECLIA

    Time frame: from baseline to 32 weeks

07

Study locations

1 site
  • Beijing Anzhen Hospital Capital Medical University City:Beijing
    Beijing, Beijing 100020, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in May 2023, 16 months.

Of 33 phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Apr 13, 2022
StartActual
Dec 31, 2021
Primary completionActual
May 8, 2023
CompletionActual
Jun 29, 2023
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05325203
Responsible party
Sponsor
First posted
Apr 13, 2022
Start date
Dec 31, 2021
Primary completion
May 8, 2023
Completion
Jun 29, 2023
Last update
Mar 18, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ongericimab

Start the discussion